August 19, 2025 — iBio, Inc. (Nasdaq: IBIO) announced the pricing of an underwritten public offering of pre-funded warrants to purchase 71,540,000 shares of iBio’s common stock, and accompanying Series G warrants representing the right to purchase shares. The combined public offering price of one pre-funded warrant and one Series G warrant is $0.699. The offering is expected to close on or about August 22, 2025.
The estimated gross proceeds are expected to be approximately $50 million. iBio intends to use the net proceeds to advance its preclinical cardiometabolic programs and to fund its working capital requirements. Leerink Partners acted as the lead bookrunner for the offering.
iBio is leveraging AI and advanced computational biology to develop biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases.
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
Source: iBio, Inc.
